Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Ashish C. Bhatia MD, FAAD Associate Editor

Christen Maria Mowad MD Advisory Board

See All Experts

featured

Published in Dermatology

Journal Scan / Research · March 20, 2024

Efficacy and Safety of Roflumilast Foam 0.3% in Adolescents and Adults With Seborrheic Dermatitis

Journal of the American Academy of Dermatology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Julie Harper MD

Journal of the American Academy of Dermatology

Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial

J Am Acad Dermatol 2024 Jan 20;[EPub Ahead of Print], A Blauvelt, ZD Draelos, L Stein Gold, J Alonso-Llamazares, N Bhatia, J DuBois, SB Forman, M Gooderham, L Green, ST Guenthner, AA Hebert, E Lain, AY Moore, KA Papp, M Zirwas, S Kato, S Snyder, D Krupa, P Burnett, DR Berk, DH Chu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Efficacy and Safety of Roflumilast Foam 0.3% in Adolescents and Adults With Seborrheic Dermatitis

Additional Info

Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial

Further Reading

Assessing Skin Cancer Diagnosis Accuracy by Lesion Type, Physician Experience, and Examination Method

Doxycycline Post-Exposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention

Association Between 5α-Reductase Inhibitor Use for Dermatologic Conditions and the Risk of Breast or Gynecologic Cancers

Efficacy of Treatment With Secukinumab in Patients With Hidradenitis Suppurativa

Local Recurrence, Metastasis, and Mortality Rates Among Patients With Thin and In Situ Melanomas

Suicidal and Self-Injurious Behaviors Among Patients With Psoriasis or Psoriatic Arthritis Treated With Biologics

Efficacy and Safety of Combined Topical 17α-Ethinyl Estradiol With Minoxidil vs Topical Minoxidil Alone in Patients With Female Pattern Hair Loss

Clinical Features and Treatment Outcomes Among Patients With Primary Cutaneous B-Cell Lymphomas

Clinical Characteristics and Outcomes of DPP-4 Inhibitor–Associated Bullous Pemphigoid

Efficacy and Safety of Tofacitinib vs Azathioprine in Patients With Alopecia Areata and Its Variants

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Recently Updated